Skip to content
value.today
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

Formerly CDF Therapeutics, Inc., Trucode Gene Repair, Inc.

Total raised
$71 M
1 round on record
Latest round
$71 M
Oct 2020
First round on record
Oct 2020
Today
Went public
See the company page

Vera Therapeutics, Inc. is listed today as Vera Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vera Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$71 MNo. 1$50 to $250 million

Vera Therapeutics, Inc.: Raise no. 1, Oct 2020

Investors in this round

23 investors had bought by the notice of Feb 25, 2021: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Vera Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$71 M of $71 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Marshall Fordyce · Executive Officer, Director
  • Andrew Cheng · Director
  • Beth Seidenberg · Director
  • Kurt von Emster · Director
  • Maha Katabi · Director
  • Patrick Enright · Director
  • Scott Morrison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $5,736,335.77 in cancelled convertible debt and does not include $28,121,124.59 sold to two investors who reside outside the United States.”

Signed by Marshall Fordyce, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 25, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vera Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2021

That is all the official record says: Vera Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Vera Therapeutics, Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Vera Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Abingworth LLPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Ares Trading S.A.Companynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Longitude Capital Partners IV, LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Longitude Venture Partners IV, L.P.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Merck Serono S.A.Companynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Sofinnova Management X, L.L.C.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Sofinnova Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 23 investors.

Largest shareholders today

Institutions holding Vera Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vera Therapeutics, Inc.
NameRoleNamed in
Marshall FordyceExecutive officerFeb 2021
Andrew ChengDirectorFeb 2021
Beth SeidenbergDirectorFeb 2021
Kurt von EmsterDirectorFeb 2021
Maha KatabiDirectorFeb 2021
Marshall FordyceDirectorFeb 2021
Patrick EnrightDirectorFeb 2021
Scott MorrisonDirectorFeb 2021

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.